Bristol Myers Squibb is following in the footsteps of some of its big pharma company peers that have rolled out direct-to-patient online platforms offering branded drugs at steep discounts. When BMS launches its new platform in January, its first product will be the plaque psoriasis medication Sotyktu.

The pharmaceutical giant said Thursday that eligible cash-pay patients who have a prescription will be able to purchase Sotyktu for $950 for a 30-day supply. That’s an 86% discount from the drug’s current $6,868 list price, a spokesperson for the company confirmed.

Payers and pharmacy benefit managers (PBMs) negotiate lower prices for insurance plans, but BMS Patient Connect is for patients who pay for their medications in cash. BMS did not specify eligibility requirements, but those who

See Full Page